Eton Pharmaceuticals has entered an exclusive U.S. licensing agreement with Aquestive Therapeutics for LIBERVANT, a diazepam buccal film designed to treat seizure clusters in epilepsy patients. The product, preferred by 71% of patients over nasal sprays, offers a portable alternative to current nasal and rectal treatments in a U.S. market worth over $450 million annually. LIBERVANT has Orphan Drug Designation, patent protection through 2038, and is expected to launch commercially in April 2027 pending FDA approval. This deal expands Eton's rare disease portfolio into neurology, providing a new growth opportunity and enhanced patient support services.
The exclusive U.S. licensing agreement for LIBERVANT® (diazepam) Buccal Film coincides with a broadly positive day for health-sector stocks on Pluang, where 98 of 150 priced US health stocks rose as of Oct 14, 2026 17:11 WIB. Notable movers include Novartis AG (NVS) at USD 144.82 with a 1.69% increase and a typical hold time of 82 days, ClearPoint Neuro Inc (CLPT) at USD 9.96 gaining 1.53% with 100% buy order activity, and Quest Diagnostics Inc (DGX) at USD 227.06 down 1.52% but also showing 100% buy order activity. This snapshot provides context for readers following developments in pharmaceutical licensing and neurology-related treatments.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
